Biotechnology Sector

In the intricate realm of environmental health science, quantifying the subtle, everyday behaviors of children—dubbed microactivities—remains a formidable challenge. These microactivities, particularly hand- and object-to-mouth contacts, significantly influence the extent of environmental exposure to harmful contaminants. Collecting accurate data on these behaviors has traditionally required painstaking manual annotation of pre-recorded videos, a process that is

The intricate relationship between touch and social interaction has garnered significant focus in recent years, particularly in the context of autism spectrum disorders (ASD). A groundbreaking study led by Mello et al. in 2025 presents a compelling exploration of how touch avoidance centralizes experiences of social touch for individuals on the autism spectrum. This research

In the rapidly evolving field of drug discovery, the integration of advanced computational techniques has begun to reshape the way researchers approach the identification and optimization of new therapeutic compounds. One of the most promising developments in this area is generative drug design, which uses algorithms to explore the vast chemical space available to scientists.

In a groundbreaking peer-reviewed viewpoint published this month in the journal Psychedelics, Professor Xiaohui Wang and colleagues present a comprehensive synthesis exploring the profound therapeutic potential of psychedelic substances in treating stress-related psychiatric disorders. This article meticulously examines emerging neurobiological mechanisms through which compounds such as psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) offer

In a groundbreaking interview published in the October 2025 issue of Genomic Psychiatry, Dr. Bruce M. Cohen, the Robertson-Steele Professor of Psychiatry at Harvard Medical School and Director of the Program for Neuropsychiatric Research at McLean Hospital, offers a transformative vision that could redefine the future of neuropsychiatric disorder research and treatment worldwide. With nearly

A landmark review published in the October 2025 issue of Psychedelics delivers an unprecedented synthesis of the latest advances in MDMA-assisted psychotherapy, capturing the compound’s complex journey from its 1912 synthesis to the cutting-edge clinical applications reshaping psychiatric treatment. Spearheaded by Dr. Kenji Hashimoto and colleagues, this comprehensive analysis intricately weaves together neurobiological mechanisms, clinical

In the field of oncology, one of the pressing challenges has always been predicting how patients will respond to chemotherapy. Researchers at the cutting edge of proteomics are actively working on unraveling the complexities surrounding this issue, particularly within the context of acute myeloid leukemia (AML). In a groundbreaking study described in the journal Clinical

In the densely populated Lower Mainland of British Columbia, a recent serological survey has revealed a strikingly high prevalence of measles antibodies among residents, underscoring the region’s robust immunization efforts. Published in the Canadian Medical Association Journal, this population-based, cross-sectional study conducted in August 2024 analyzed blood samples from over 1,000 individuals spanning multiple age

The impact of Long COVID has become an increasingly prominent topic within the realm of healthcare research, particularly as we strive to comprehend the long-term effects of SARS-CoV-2. In a groundbreaking study, Troxel, Krishnan, and Verduzco-Gutierrez lay the groundwork for a nuanced understanding of Long COVID with their paper titled “The 2024 NASEM Long COVID

In the rapidly modernizing landscapes of China, a new study has shed light on a critical, yet alarming issue: the urban-rural disparity in preterm neonatal mortality rates. Conducted by researchers Liu, Kang, and Zou, this extensive retrospective study compiles data that poignantly illustrates how geographic and socioeconomic factors contribute to the health outcomes of newborns

In recent years, the concept of trained immunity has been revolutionizing our understanding of how the immune system adapts to threats in a manner previously thought to be exclusive to adaptive immunity. In a groundbreaking new study published in Cell Research in 2025, Schlüter, van Elsas, Priem, and colleagues delve deeply into the phenomenon of

Researchers are continually pushing the boundaries of technological innovation in medical devices, particularly in the field of ultrasound imaging. Recently, an ambitious research team led by Dr. Byung Chul Lee from the Korea Institute of Science and Technology (KIST) has unveiled a significant advancement that promises to reshape how ultrasound devices are conceptualized and utilized.

Hearing Mother’s Voice Sparks Accelerated Language Pathway Development in Premature Infant Brain A groundbreaking study led by Stanford Medicine researchers has demonstrated that regular exposure to a mother’s voice can significantly enhance the development of critical language-processing pathways in the brains of premature infants. This novel intervention, involving recorded maternal speech played during the latter

In an exciting breakthrough for the world of computing, researchers have unveiled a revolutionary approach that leverages the unique properties of nonlinear phononics, specifically on the versatile platform of lithium niobate. This pioneering work, centered on synthetic-domain computing, heralds a new era for analogue computing, promising to enhance the efficiency of arithmetic operations while tackling

In the realm of forensic medicine, accurately determining the post-mortem interval (PMI)—the time elapsed since death—remains a formidable challenge with profound implications for criminal investigations and legal proceedings. Recent advancements in molecular biology herald a transformative era in PMI estimation, offering unprecedented precision and reliability. The latest comprehensive review by He, Song, and Fu published

In recent years, the discourse surrounding patient-centered care has gained significant traction, particularly within the realm of oncology. A pivotal study conducted by Eskiler, Bilir, and Altunisik delves into the intricacies of patient-centered communication and its correlation with health outcomes among Turkish cancer patients undergoing chemotherapy. This research unveils compelling insights, highlighting the essential roles

Researchers have recently unveiled a novel actinobacterium strain designated as cg36^T, isolated from the rhizosphere of a plant species known as Cyclosorus parasiticus. This groundbreaking study presents a comprehensive polyphasic taxonomic investigation which not only identifies this new strain but also places it within a well-defined taxonomic framework. The rhizosphere, the region of soil that

Innovations in CRISPR diagnostics have ushered in a new era in disease detection and treatment, allowing for unprecedented sensitivity and multiplexing capabilities that revolutionize healthcare. The latest research conducted by Siddiqui, Welch, and Nguyen opens up intriguing avenues toward enhancing these groundbreaking diagnostic tools through bead-based technologies. Their study delves deep into the mechanics of

In a significant breakthrough for both public health and environmental sustainability, recent research by Flynn et al. presents a compelling argument for the adoption of a “dish swap” approach to weekly meal planning. This innovative concept involves the strategic exchange of food items within weekly menus, thereby optimizing nutrient intake while simultaneously reducing ecological impacts.

A groundbreaking study led by Imam, M.S. and collaborators, unveiled a nanoparticle-modified paper-based analytical sensor that promises to revolutionize the diagnosis of olfactory dysfunction and its possible correlation with specific calcium levels in human nasal secretions. This innovation merges the fields of nanotechnology and sensory health, offering a unique approach to a widely overlooked aspect

Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so special. The post Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The California biotech is developing a new drug class in hopes of redefining the standard of care for several allergic diseases.

Tvardi Therapeutics has failed its first big test as a public company. Months after joining Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in a phase 2 trial of its idiopathic pulmonary fibrosis prospect.

Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months, keeping alive one of the last remaining hopes for this once-hyped modality.

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the division’s 250 employees, according to a Danish publication.

Johnson & Johnson may be looking to deepen its relationship with immunology partner Protagonist Therapeutics with a takeover deal, The Wall Street Journal reports.

We were on the ground in Barcelona speaking to biotech companies, university technology transfer offices, and top pharma firms about their experience at BIOSPAIN and their progress towards securing partnerships. The post Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next step appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Cabaletta Bio’s CAR-T cell therapy successfully eliminated the overreactive B cells of two patients with an autoimmune disease, even without any preconditioning chemotherapy, pleasing investors and analysts alike and providing hope of less toxic autoimmune treatments.

In an Oct. 9 discussion about innovation, resilience and the road ahead, panelists explored how federal uncertainty has affected the biotech sector, while also highlighting potential silver linings in the current environment.

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a preclinical CD19 autoimmune program.

In this week's podcast we talked with Kevin Eisenfrats, CEO of Contraline, about contraception, male contraception. The post Contraline’s ADAM in the clinic: towards a new era of male contraception? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Shuttle Pharmaceuticals has rocketed into the AI-driven drug discovery space via the planned $10 million acquisition of Molecule.ai.

It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by the public markets.

Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare genetic form of deafness as it plans for a potential FDA filing later this year.

Transparency is often a word pharma companies like to use, but in practice, they rarely live up to the ideal. AstraZeneca is trying to be truly transparent with its new Discovery Centre.

Patient-centric strategies and global partnerships drive progress in eye disease research

Two ex-Moderna leaders have hit a milestone in their new endeavor, closing a $325 million inaugural fund for their biotech venture capital firm called Ascenta.

Peter Marks, M.D., Ph.D., the former head of the FDA’s Center for Biologics Evaluation and Research (CBER), has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks served as CBER chief for nearly a decade until butting heads with Department of Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.

As Asabys Partners has rolled Aliath Bioventures into its platform, it's worth asking if European biotech VCs are under pressure to scale. The post Are European biotech VCs under pressure to scale? Time to get pragmatic  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstructive pulmonary disease.

Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.

England's AviadoBio is looking to China as a potential source of additional gene therapies, securing an option to a $413 million biobucks deal that could deliver a rare eye disease candidate.

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market.

Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug.

AAIC 2025 spotlights inflammation in Alzheimer’s; InMed’s INM-901 reduces key biomarkers linked to disease progression

Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals were signed. The post Top biotech deals in September 2025  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

PFAS's environmental persistence and health risks are prompting regulations impacting medical devices. Discover key insights and solutions from the experts at Battelle.

Here are six mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. The post Six companies leading the mRNA revolution in biotechnology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). The post AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

uniQure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025. The post The biggest biotech funding rounds in September 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

This week, we discussed funding with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B round. The post Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Merck’s decision to back out of its $1 billion expansion comes as U.K. investments in life sciences declines. The post Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible. The post Asthma study suggests lung scarring may be reversible  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Driven by CASGEVY's success, the CRISPR field is experiencing substantial growth with a new wave of companies. The post CRISPR technology’s next wave: Ten companies to watch in 2025  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.